B.C.'s Applied Biologicals Commercializes R&D With Government Support
Applied Biological Materials Inc. of British Columbia has succeeded in commercializing a new detection system for genetic information.
Location Canada 2011
The company has developed a microRNA (miRNA) expression and detection system where miRNA is known to regulate the genome, which is the basic foundation for human health and medical conditions. The system is used in life science research and biotechnology industries across Canada and the world.
"Research in miRNA holds great promise for the life science community and can ultimately contribute to innovative diagnostic assays and therapeutic modalities. Through government of Canada support, Applied Biological Materials Inc. has been elevated to become one of the world's top players in this technology," said CEO Dr. Peter Li. "Our dominant position has opened and will continue to open new job opportunities in Canada. In short, it is almost impossible for Applied Biological Materials Inc. to take on cutting-edge research and development, like the miRNA project, without the government's support."
Project Announcements
Northern Transformer Plans Innisfil, Ontario, Canada, Manufacturing Operations
10/02/2025
Ranovus Expands Ottawa, Ontario, Semiconductor Operations
08/29/2025
Canada-Based Mancuso Chemicals Plans Pachuta, Mississippi, Logistics-Distribution Operations
08/11/2025
Ferrero Expands Brantford, Ontario, Canada, Production Operations
04/19/2025
Minth Group Plans Windsor, Ontario, Canada, Manufacturing Operations
04/07/2025
Siemens Canada Expands Oakville, Ontario, Operations
04/03/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025